TherapeuticsMD, Inc. TXMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-78.93
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.0M | -$569,000 | — | — | $26.9M |
| 2024 | $1.8M | -$2.2M | — | — | $27.4M |
| 2023 | $1.3M | -$10.3M | $1.3M | — | $29.3M |
| 2022 | $70.0M | $112.0M | $68.6M | — | $35.1M |
| 2021 | $2.6M | -$172.4M | $1.2M | -$55.2M | -$93.6M |
| 2020 | $64.9M | -$183.5M | $48.9M | -$159.7M | -$124.0M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -78.93 (distress)
- Working capital / assets 0.257
- Retained earnings / assets -25.292
- EBIT / assets -0.117
- Equity / liabilities 2.493
Source: SEC EDGAR filings · CIK 0000025743 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.